ACET
NASDAQ HealthcareAdicet Bio, Inc. - Common Stock
Biotechnology
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts.
๐ Market Data
| Price | $8.20 |
|---|---|
| Volume | 118,994 |
| Market Cap | 76.66M |
| Beta | 1.580 |
| RSI (14-Day) | 69.9 |
| 200-Day MA | $9.80 |
| 50-Day MA | $7.26 |
| 52-Week High | $17.44 |
| 52-Week Low | $6.01 |
| Forward P/E | -2.44 |
| Price / Book | 0.55 |
๐ฏ Investment Strategy Scores
ACET scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Over-Hyped (82/100) โ this strategy Overbought stocks (potential short candidates).
Lowest fit among scored strategies: ๐ Institutional Whale (1/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find ACET in your text
Paste any article, transcript, or post โ the tool will extract ACET and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.